[ad_1]
In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Mitomycin C market for 2018-2023.
Mitomycin C market, Mitomycin C is an antibiotic which acts as a double-stranded DNA alkylating agent. It covalently crosslinks DNA, inhibiting DNA synthesis and cell proliferation It acts by way of reductive activation either through low pH or NAD(P)H:quinone oxidoreductase (DT-diaphorase) or NADH cytochrome c reductase (Mao et al.; Cummings et al.).
In the last several years, Global market of Mitomycin C was experienced an upward trend rapidly, with an average growth rate of 4.76%. In 2016, Global Revenue of Mitomycin C is nearly 119.83 M USD; the actual production is about 17370 K Unit.
The global average price of Mitomycin C is in the increasing trend, from 6.30 USD/Unit in 2012 to 6.90 USD/Unit in 2016. With the situation of global economy, prices will be in increasing trend in the following five years.
The classification of Mitomycin C includes 2 Mg, 10 Mg, 40 Mg, and others. The proportion of 2 Mg in 2016 is about 41.5%, and the proportion is in decreasing trend from 2012 to 2016.
Mitomycin C is widely used in Cancer Treatment, Ophthalmic Use, and other field. The most proportion of Mitomycin C is Cancer Treatment, and the proportion in 2016 is 69%. The trend of Cancer Treatment is decreasing.
Japan is the largest supplier of Mitomycin C, with a production market share nearly 26.5% in 2016. India is the second largest supplier of Mitomycin C Media, enjoying production market share nearly 25% in 2016.
North America is the largest consumption place, with a consumption market share nearly 36% in 2016. Following North America, Europe is the second largest consumption place with the consumption market share of 32.6%.
Over the next five years, LPI(LP Information) projects that Mitomycin C will register a -2.3% CAGR in terms of revenue, reach US$ 100 million by 2023, from US$ 120 million in 2017.
This report presents a comprehensive overview, market shares, and growth opportunities of Mitomycin C market by product type, application, key manufacturers and key regions.
To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:
Segmentation by product type:
2 Mg
10 Mg
40 Mg
Other
Segmentation by application:
Cancer Treatment
Ophthalmic Use
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Enquire Here & check discount for report@:
https://www.reporthive.com/enquiry.php?id=1565680&req_type=disc
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
Kyowa-kirin
Intas Pharmaceuticals
Teva
Bristol-Myers Squibb
Aspen
Speciality European Pharma
Alkem Laboratories
Varifarma
APOGEPHA
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives:
· To study and analyze the global Mitomycin C consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
· To understand the structure of Mitomycin C market by identifying its various subsegments.
· Focuses on the key global Mitomycin C manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
· To analyze the Mitomycin C with respect to individual growth trends, future prospects, and their contribution to the total market.
· To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
· To project the consumption of Mitomycin C submarkets, with respect to key regions (along with their respective key countries).
· To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
· To strategically profile the key players and comprehensively analyze their growth strategies.
Read full Research Report Study@: https://www.reporthive.com/enquiry.php?id=1565680&req_type=purch
Table of Contents:
Chapter One: Scope of the Report
Chapter Two: Executive Summary
Chapter Three: Global Mitomycin C by Players
Chapter Four: Mitomycin C by Regions
Chapter Five: Americas
Chapter Six: APAC
Chapter Seven: Europe
Chapter Eight: Middle East & Africa
Chapter Nine: Market Drivers, Challenges and Trends
Chapter Ten: Marketing, Distributors and Customer
Read More…
List of Tables and Figures:
Figure Mitomycin C Consumed in Cancer Treatment
Figure Global Mitomycin C Market: Cancer Treatment (2013-2018) (K Units)
Figure Global Mitomycin C Market: Cancer Treatment (2013-2018) ($ Millions)
Figure Global Cancer Treatment YoY Growth ($ Millions)
Figure Mitomycin C Consumed in Ophthalmic Use
Figure Global Mitomycin C Market: Ophthalmic Use (2013-2018) (K Units)
Figure Global Mitomycin C Market: Ophthalmic Use (2013-2018) ($ Millions)
Figure Global Ophthalmic Use YoY Growth ($ Millions) and know more…